Securities Code: 002932
Securities Abbreviation: *ST Mingde
Announcement Number: 2026-037
Wuhan Mingde Biotechnology Co., Ltd. (hereinafter referred to as "the Company") and all members of the Board of Directors guarantee that the content of this information disclosure is true, accurate, and complete, with no false records, misleading statements, or significant omissions.
1. Overview of the Investment Fund
On June 20, 2023, the Company held the fifth meeting of the fourth Board of Directors, which reviewed and approved the proposal on participating in the establishment of a private equity investment fund and related transactions. The Company agreed to invest in the establishment of the Wuhan Mingjun Hezong Venture Capital Fund Partnership (Limited Partnership) (hereinafter referred to as "the Fund") with Mingxi Venture Capital Management (Wuhan) Co., Ltd. (hereinafter referred to as "Mingxi Venture Capital"), Ms. Chen Lili, and Lhasa Junqi Enterprise Management Co., Ltd. (hereinafter referred to as "Lhasa Junqi"). The total subscribed capital of the Fund is RMB 235 million, of which the Company contributes RMB 175 million from its own funds. On July 19, 2023, the Fund completed its filing.
On September 22, 2023, the Company held the eighth meeting of the fourth Board of Directors, which reviewed and approved the proposal for the Company's controlling subsidiary, Guangdong Mingzhi Medical Laboratory Co., Ltd. (hereinafter referred to as "Guangdong Mingzhi"), to participate as a limited partner with an investment of RMB 30 million. On the same day, the Company signed the Limited Partnership Agreement of the Wuhan Mingjun Hezong Venture Capital Fund Partnership (Limited Partnership) with Mingxi Venture Capital, Lhasa Junqi, Wuhan Industrial Development Fund Co., Ltd., Guangdong Mingzhi, Ms. Chen Lili, Ms. Wang Ying, Ms. Zhou Qin, Mr. Chen Xintao, and Mr. Wang Hanying, increasing the Fund's scale from RMB 235 million to RMB 412.5 million.